NCT04659122终止1 期
Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection or Respiratory Failure Secondary to Severe Community Acquired Pneumonia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Determining the highest-tolerated & safety-tested AT-100 dose
研究概览
简要总结
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired pneumonia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is an adult ≥18 years of age.
- •The subject has documented, laboratory-confirmed SARS-CoV-2 infection within 2 weeks prior to enrollment, or meets criteria for severe community acquired pneumonia (CAP) specified in inclusion 3 below.
- •The subject has severe SARS-CoV-2 infection requiring intubation and mechanical ventilation. Or, the subject is admitted for severe CAP with respiratory failure as demonstrated by the following:
- •i. Respiratory failure requiring intubation and mechanical ventilation, and
- •ii. A clinical diagnosis of CAP that includes radiographic findings of new pulmonary infiltrate(s) consistent with CAP plus any one of the following on admission to the hospital:
- •Fever (Temperature > 38.0°C),
- •Hypothermia (Temperature < 36.0°C),
- •Leukocytosis with White Blood Cells (WBC) > 10,000 cells/µL or immature band forms > 10%,
- •Leukopenia with WBC < 4,000 cells/µL, or
- •Hypotension Mean Arterial Pressure (MAP) < 70 mmHg, requiring the initiation of vasopressor support.
- •The subject has been receiving mechanical ventilation for <72 hours.
- •The subject is receiving mechanical ventilation due to respiratory disease that is primarily due to SARS-CoV-2 infection or CAP.
- •The subject, or legally authorized representative if acting on the subject's behalf, is able to provide informed consent.
排除标准
- •The subject refuses to participate, or the subject's legally authorized representative acting on the subject's behalf refuses the subject's participation.
- •The subject is pregnant or breastfeeding.
- •The subject is anticipated to be transferred to another hospital that is not a study site within 36 hours of enrollment.
- •The subject has received or is receiving extracorporeal membrane oxygenation (ECMO) treatment for COVID-19 or CAP treatment.
- •The subject has Human Immunodeficiency virus (HIV) under highly active antiretroviral therapy (HAART).
- •The subject has cancer and is receiving chemotherapy treatment at any time during trial duration, or has received chemotherapy treatment within 30 days of trial enrollment.
- •The subject has a prior history of lung transplant, lobectomy, or other significant lung surgeries that would indicate an already compromised lung.
- •The subject has known pulmonary air leaks, such as pneumothorax and pneumomediastinum.
- •Concurrent enrollment in an investigational product, device, or treatment trial or is projected to participate in any other trial that alters the standard of care during the period of this study
- •The subject has a known allergy, sensitivity, or contraindication to any component of the test article (AT-100).
- •The subject has any active do not resuscitate (DNR)-Comfort Care (CC) order in place. Subjects with an active DNR-Comfort Care Arrest (CCA) are not excluded.
- •The subject's intubation, re-intubation, or remaining on intubation is not per clinical standard-of-care and is solely for the purposes of administration of study drug.
- •The subject has any condition or is in a situation in which, in the Investigator's judgement, puts the subject at significant risk, could confound the trial results, or may significantly interfere with the subject's trial participation.
研究组 & 干预措施
AT-100 150 mg
Experimental
Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe & tolerated.
干预措施: AT-100 (Biological)
AT-100 75 mg or 150 mg (Optional Cohort)
Experimental
Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe & tolerated dose as determined by the prior 2 dosing levels.
干预措施: AT-100 (Biological)
AT-100 75 mg
Experimental
Once daily AT-100 via intratracheal administration for up to 7 doses.
干预措施: AT-100 (Biological)
结局指标
主要结局
Determining the highest-tolerated & safety-tested AT-100 dose
时间窗: From time of initial AT-100 dosing until the end of the dosing period, up to 7 days
Dose escalation of AT-100 will occur to determine the maximum dose (in mg) that produces no significant Dose Limiting Toxicities or dose-related Adverse Events (AEs).
次要结局
- Reduction in mechanical ventilation(From mechanical ventilation initiation up to Day 28)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi SarcomaRefractory HIV Associated Kaposi SarcomaNCT05646082Imperial College London20
已完成
2 期
Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of AgePain, PostoperativeNCT02633969Iroko Pharmaceuticals, LLC30
终止
2 期
ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaLeiomyosarcomaLiposarcomaNCT05116683Benjamin Izar4
已完成
2 期
Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of AgePain, PostoperativeNCT02424578Iroko Pharmaceuticals, LLC30
已完成
1 期
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical CarcinomaAdrenal CancerACCAdrenocortical CarcinomaNCT01898715Millendo Therapeutics, Inc.63